Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1.
Epidemiological and experimental reports have linked mild-to-moderate wine and/or grape consumption to a lowered incidence of cardiovascular, cerebrovascular, and peripheral vascular risk. This study revealed that resveratrol, an enriched bioactive polyphenol in red wine, selectively induces heme oxygenase 1 (HO1) in a dose- and time-dependent manner in cultured mouse cortical neuronal cells and provides neuroprotection from free-radical or excitotoxicity damage. This protection was lost when cells were treated with a protein synthesis or heme oxygenase inhibitor, suggesting that HO1 induction is at least partially required for resveratrol's prophylactic properties. Furthermore, resveratrol pretreatment dose-dependently protected mice subjected to an optimized ischemic-reperfusion stroke model. Mice in which HO1 was selectively deleted lost most, if not all, of the beneficial effects. Together, the data suggest a potential intracellular pathway by which resveratrol can provide cell/organ resistance against neuropathological conditions.
Sakata
Yoshihito
Y
Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Zhuang
Hean
H
Kwansa
Herman
H
Koehler
Raymond C
RC
Doré
Sylvain
S
D000704:Analysis of Variance; D000818:Animals; D015153:Blotting, Western; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D051547:Heme Oxygenase-1 / Q000235:genetics / Q000378:metabolism*; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology; D000077185:Resveratrol; D018709:Statistics, Nonparametric; D013267:Stilbenes / Q000494:pharmacology*; D013997:Time Factors
D018696:Neuroprotective Agents; D013267:Stilbenes; D051547:Heme Oxygenase-1; D000077185:Resveratrol
Mol Med. 1999 Oct;5(10):656-63
10602774
Ageing Res Rev. 2008 Jan;7(1):43-8
17913594
J Neurosci Res. 2007 Aug 15;85(11):2433-40
17600836
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2445-50
10051662
Nat Rev Drug Discov. 2006 Jun;5(6):493-506
16732220
Food Chem Toxicol. 1995 Dec;33(12):1061-80
8847003
J Cardiovasc Pharmacol. 2000 Feb;35(2):263-8
10672859
PLoS One. 2008 Jun 04;3(6):e2264
18523577
Brain Res. 2004 Aug 13;1017(1-2):98-107
15261105
Mol Cell Biol. 2003 Jan;23(1):38-54
12482959
Clin Chim Acta. 1995 Mar 31;235(2):207-19
7554275
Am J Surg. 2000 Nov;180(5):357-61
11137687
Ann N Y Acad Sci. 2003 May;993:276-86; discussion 287-8
12853318
Lancet. 1993 Apr 24;341(8852):1103-4
8097009
Nat Prod Rep. 1996 Aug;13(4):265-73
8760864
J Stroke Cerebrovasc Dis. 2006 Jul-Aug;15(4):133-8
17904065
Lancet. 1992 Jun 20;339(8808):1523-6
1351198
Can J Physiol Pharmacol. 2009 Apr;87(4):275-86
19370081
Endocr Metab Immune Disord Drug Targets. 2008 Jun;8(2):89-98
18537695